Active substance
Tafluprost
- SFDA 2
- US FDA 4
- US price lines 2
- NHS prices 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Novanza | 0.015 mg/ml | Eye drops, solution in single-dose container · Ophthalmic use | 30 Single Dose Container | SAR 56.55 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| SAFLUTAN 15MCG/ML EYE DROPS | 15 µg | Eye drops, solution in single-dose container · Ophthalmic use | 30 Single Dose Container | SAR 60.60 | NCE · Prescription | MUNDIPHARMA PTY LTD | Valid |
Indications — CHI Daman Drug Formulary
OPEN ANGLE GLUCOMA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZIOPTAN | 0.0015% | solution/drops · ophthalmic | THEA PHARMA | Prescription | 10 Feb 2012 |
| TAFLUPROST | 0.0015% | solution/drops · ophthalmic | MICRO LABS | Prescription | 19 Aug 2019 |
| TAFLUPROST | 0.0015% | solution/drops · ophthalmic | SANDOZ | Prescription | 28 Jan 2022 |
| TAFLUPROST | 0.0015% | solution/drops · ophthalmic | INGENUS PHARMS LLC | Prescription | 5 Apr 2024 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TAFLUPROST 0.0015% EYE DROP | $2.4535 | per EA | 23 Sep 2026 |
| US NADAC | ZIOPTAN 0.0015% EYE DROP | $8.48561 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Tafluprost 15micrograms/ml eye drops | £11.39 | 3 ml | 1 Oct 2026 |
| NHS Drug Tariff | Tafluprost 15micrograms/ml eye drops 0.3ml unit dose preservative free | £12.20 | 30 unit dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 25 Feb 2026 ZIOPTAN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.